IL142906A0 - Methods and compositions for treating or preventing peripheral neuropathies - Google Patents

Methods and compositions for treating or preventing peripheral neuropathies

Info

Publication number
IL142906A0
IL142906A0 IL14290699A IL14290699A IL142906A0 IL 142906 A0 IL142906 A0 IL 142906A0 IL 14290699 A IL14290699 A IL 14290699A IL 14290699 A IL14290699 A IL 14290699A IL 142906 A0 IL142906 A0 IL 142906A0
Authority
IL
Israel
Prior art keywords
compositions
treating
methods
peripheral neuropathies
preventing peripheral
Prior art date
Application number
IL14290699A
Other languages
English (en)
Original Assignee
Biogen Inc
Ontogeny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Ontogeny Inc filed Critical Biogen Inc
Publication of IL142906A0 publication Critical patent/IL142906A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
IL14290699A 1998-11-06 1999-11-08 Methods and compositions for treating or preventing peripheral neuropathies IL142906A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/187,387 US20030083242A1 (en) 1998-11-06 1998-11-06 Methods and compositions for treating or preventing peripheral neuropathies
PCT/US1999/026334 WO2000027422A2 (en) 1998-11-06 1999-11-08 Methods and compositions for treating or preventing peripheral neuropathies

Publications (1)

Publication Number Publication Date
IL142906A0 true IL142906A0 (en) 2002-04-21

Family

ID=22688771

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14290699A IL142906A0 (en) 1998-11-06 1999-11-08 Methods and compositions for treating or preventing peripheral neuropathies

Country Status (7)

Country Link
US (1) US20030083242A1 (ja)
EP (1) EP1126865A2 (ja)
JP (1) JP2002529423A (ja)
AU (1) AU776265B2 (ja)
CA (1) CA2349498A1 (ja)
IL (1) IL142906A0 (ja)
WO (1) WO2000027422A2 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same
AU2429201A (en) * 1999-12-10 2001-06-18 General Hospital Corporation, The Methods to stimulate insulin production by pancreatic beta-cells
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
ES2250377T5 (es) * 2000-03-30 2010-04-06 Curis, Inc. Moleculas organicas pequeñas reguladoras de la proliferacion celular.
EP1671634A1 (en) * 2000-03-30 2006-06-21 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
AU2001259252A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Neuroprotective compositions
WO2001098344A2 (en) * 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20030157185A1 (en) * 2002-02-08 2003-08-21 Lou Paradise Topical treatment of neuropathy
US7871647B1 (en) * 2002-02-08 2011-01-18 TPR International, Inc Topical treatment of neuropathy
KR100533794B1 (ko) * 2003-10-02 2005-12-07 주식회사 프로젠 인간 난포자극 호르몬을 대량으로 생산하는 방법
US20050208671A1 (en) * 2003-12-26 2005-09-22 Nof Corporation Method of analyzing the ratio of activation of terminals of polyoxyalkylene derivatives
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
WO2006079068A2 (en) * 2005-01-20 2006-07-27 University Of Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
WO2007033063A2 (en) * 2005-09-12 2007-03-22 The Board Of Regents Of The University Of Texas System Regulation of the hedgehog signaling pathway and uses thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US20070275008A1 (en) * 2006-05-26 2007-11-29 Olalde Rangel Jose A Synergistic Diabetic Phyto-Nutraceutical Composition
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
US7553501B2 (en) * 2006-11-16 2009-06-30 Jose Angel Olalde Rangel Immune phyto-neutraceutical composition
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
PT2670753T (pt) 2011-01-31 2017-01-10 Novartis Ag Novos derivados heterocíclicos
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
EP3076969B1 (en) 2013-12-06 2021-09-01 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
KR20180073674A (ko) 2015-11-02 2018-07-02 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN106814171B (zh) * 2017-01-18 2019-02-19 江南大学 一种利用数学模型确定食用油中植物甾醇添加量的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789543A (en) * 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
NZ278765A (en) * 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
US7144997B2 (en) * 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
CA2302780A1 (en) * 1997-08-29 1999-03-04 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
WO1999029854A1 (en) * 1997-12-08 1999-06-17 Ontogeny, Inc. Human patched genes and proteins, and uses related thereto

Also Published As

Publication number Publication date
US20030083242A1 (en) 2003-05-01
EP1126865A2 (en) 2001-08-29
AU776265B2 (en) 2004-09-02
JP2002529423A (ja) 2002-09-10
WO2000027422A3 (en) 2000-11-09
CA2349498A1 (en) 2000-05-18
WO2000027422A2 (en) 2000-05-18
AU1611600A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
GR20010300060T1 (en) Methods and compositions for treating and preventing mucositis
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU6053900A (en) Compositions for treating or preventing neurodegeneration and cognitive decline
PL352014A1 (en) Dietetic of pharmacological composition for preventing or treating hyperoxaluria
HK1031174A1 (en) Compositions and methods for treating diabetes
IL127664A (en) Compositions for the treatment and prevention of cachexia
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
EP1109548A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING BONE DISEASES USING TOCOTRIENOLE
ZA981600B (en) Methods and compositions for treating stickies
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
HK1042847A1 (zh) 骨代謝異常症治療劑
EP1089731A4 (en) COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
HUP0102995A3 (en) Agents and method for the protective treatment of wood
GB9805744D0 (en) Biocidal compositions and treatments
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
AU5243999A (en) Methods and compositions for treating and preventing substance abuse using moclobemide
EP1089732A4 (en) COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
GB9810540D0 (en) Methods and compositions for preventing and treating bone loss

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees